ES2509883T3 - Antagonistas de glucagón - Google Patents
Antagonistas de glucagón Download PDFInfo
- Publication number
- ES2509883T3 ES2509883T3 ES08845852.6T ES08845852T ES2509883T3 ES 2509883 T3 ES2509883 T3 ES 2509883T3 ES 08845852 T ES08845852 T ES 08845852T ES 2509883 T3 ES2509883 T3 ES 2509883T3
- Authority
- ES
- Spain
- Prior art keywords
- glucagon
- kda peg
- seq
- pla6
- antagonism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Antagonista de glucagón que comprende la secuencia de la SEQ ID NO: 42, o un derivado de la SEQ ID NO: 42 que difiere de la SEQ ID NO: 42 por sustituciones de aminoácidos en una a tres posiciones de aminoácidos seleccionadas entre las posiciones 5, 6, 8, 9, 12, 13 y 14 de la SEQ ID NO: 42, en la que el NH2 N-terminal del antagonista de glucagón "o derivado" está sustituido por un grupo hidroxilo, de manera que la Phe en la posición 1 del antagonista de glucagón es ácido fenil láctico (PLA), y sales farmacéuticamente del mismo.
Description
E08845852
02-10-2014
selectivamente sin la restauración del agonismo del glucagón. Los análogos Phe6 nativos sorprendentemente demuestran una restauración del agonismo cuando se pegilan. Sin embargo, esta restauración del agonismo no se observa en los análogos peptídicos PLA6. Se examinaron varios sitios de pegilación específicos, incluyendo las posiciones de aminoácido 8, 11 y 24 (en relación con el péptido de glucagón nativo). La pegilación en la posición 24 del análogo PLA6 muestra el antagonismo de glucagón más potente y selectivo.
Tabla 12: Análogos de glucagón truncados en N-terminal PEGilados y sus actividades de antagonismo del glucagón
- Péptido
- IC50 (nM) (unión al receptor) IC50 (nM) (cAMP, inhibición de glucagón 0,2 mM)
- [C8 (20 kDa PEG), E9]Glucagón (aa6-29)-NH2
- > 1000 sin antagonismo
- [PLA6, C8 (20 kDa PEG), E9]Glucagón (aa6-29)-NH2
- 303 ± 14 236
- [E9, C11 (20 kDa PEG)]Glucagón (aa6-29)-NH2
- > 1000 sin antagonismo
- [PLA6, E9, C11 (20 kDa PEG)]Glucagón (aa6-29)-NH2
- 776 ± 161 664
- [E9, C24 (20 kDa PEG)]Glucagón (aa6-29)-NH2
- > 1000 sin antagonismo
- [PLA6, E9, C24 (20 kDa PEG)]Glucagón (aa6-29)-NH2
- 90 ± 7 126
- [MCA6, E9, C24 (20 kDa PEG)]Glucagón (aa6-29)-NH2
- 208 ± 57 sin antagonismo
- [C5 (1,2 kDa PEG), E9]Glucagón (aa5-29)-NH2
- 1081 ± 268 2281
- [C5 (5 kDa PEG), E9]Glucagón (aa5-29)-NH2
- 634 ± 174 1608
- [C5 (20 kDa PEG), E9]Glucagón (aa5-29)-NH2
- 331 ± 74 976
- [d-Cys5 (20 kDa PEG), E9]Glucagón (aa5-29)-NH2
- > 10000 14764
- [K5(CH2CH2S-20 kDa PEG), E9]Glucagón (aa5-29)-NH2
- > 10000 sin antagonismo
- 3,4 kDaPEG-dímero [C5, E9]Glucagón (aa5-29)-NH2
- 435 ± 256 1343
- [PLA6, C8 (1,2 kDa PEG),E9] Glucagón (aa6-29)-NH2
- 220 ± 36 sin antagonismo
- [PLA6, C8 (5 kDa PEG),E9] Glucagón (aa6-29)-NH2
- 948 ± 297 216
- [PLA6, C8 (20 kDa PEG),E9] Glucagón (aa6-29)-NH2
- 303 ± 14 92
- [PLA6, E9, C24 (1,2 kDa PEG)] Glucagón (aa6-29)-NH2
- 4,7 ± 0,4 18
- [PLA6, E9, C24 (20 kDa PEG)] Glucagón (aa6-29)-NH2
- 90 ± 7 126
- [MCA6, E9, C24 (20 kDa PEG)] Glucagón (aa6-29)-NH2
- 208 ± 57 sin antagonismo
- [Phe6, E9, C24 (20 kDa PEG)] Glucagón (aa6-29)-NH2
- > 10000 sin antagonismo
[0279] Los antagonistas de glucagón descritos en este documento se acilan de la siguiente manera: Los péptidos acilados y/o PEGilados se preparan de la siguiente manera. Los péptidos se sintetizan en una resina de soporte sólido utilizando un sintetizador de péptidos CS Bio 4886 o un sintetizador de péptidos Applied Biosystems
15 430A. Se utiliza química de neutralización in situ tal como se describe por Schnolzer et al., Int. J. Peptide Protein Res.
40: 180-193 (1992). Para los péptidos acilados, el residuo de aminoácido diana a acilar (por ejemplo, la posición diez) se sustituye por un resduo de N ε-Fmoc lisina. El tratamiento del péptido protegido N-terminalmente con BOC completado con piperidina al 20% en DMF durante 30 minutos elimina los grupos FMOC/formilo. El acoplamiento al residuo de Lys con el ε-amino libre se logra mediante el acoplamiento de un exceso molar de diez veces de un aminoácido espaciador
20 protegido con FMOC (por ejemplo, FMOC-(N-BOC)-triptófano-OH) o la cadena de acilo (por ejemplo, C17-COOH) y el reactivo de acoplamiento PyBOP o DEPBT en DMF/DIEA. La eliminación posterior del grupo Fmoc del aminoácido espaciador va seguida por la repetición del acoplamiento con una cadena de acilo. El tratamiento final con 100% de TFA da lugar a la eliminación de cualquier grupo protectore de la cadena lateral y el grupo BOC N-terminal. Las resinas de
49
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98378307P | 2007-10-30 | 2007-10-30 | |
US983783P | 2007-10-30 | ||
PCT/US2008/080973 WO2009058662A2 (en) | 2007-10-30 | 2008-10-23 | Glucagon antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2509883T3 true ES2509883T3 (es) | 2014-10-20 |
Family
ID=40591715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08845852.6T Active ES2509883T3 (es) | 2007-10-30 | 2008-10-23 | Antagonistas de glucagón |
Country Status (13)
Country | Link |
---|---|
US (1) | US8981047B2 (es) |
EP (1) | EP2217701B9 (es) |
JP (1) | JP5669582B2 (es) |
AR (1) | AR069110A1 (es) |
AU (1) | AU2008318986B2 (es) |
CA (1) | CA2707861A1 (es) |
CL (1) | CL2008003222A1 (es) |
ES (1) | ES2509883T3 (es) |
HK (1) | HK1143994A1 (es) |
MX (1) | MX2010004297A (es) |
PE (1) | PE20091393A1 (es) |
TW (1) | TW200920404A (es) |
WO (1) | WO2009058662A2 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056362A2 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
EA019203B9 (ru) | 2008-06-17 | 2014-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты глюкагонового рецептора/glp-1-рецептора |
KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
TWI489992B (zh) | 2008-12-19 | 2015-07-01 | 印地安那大學研究及技術公司 | 醯胺系胰高血糖素超級家族之胜肽前驅藥物 |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
JP2013510834A (ja) | 2009-11-16 | 2013-03-28 | メリテク | [1,5]‐ジアゾシン誘導体 |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20130053310A1 (en) * | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
EP2635296B1 (en) | 2010-11-03 | 2014-12-24 | Arecor Limited | Novel composition comprising glucagon |
PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
GEP20176629B (en) | 2011-06-22 | 2017-02-27 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
MX2013015168A (es) | 2011-06-22 | 2014-03-31 | Univ Indiana Res & Tech Corp | Co-agonista del receptor de glucagon/glp-1. |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
KR20140097151A (ko) | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
US9452225B2 (en) | 2012-03-01 | 2016-09-27 | Novo Nordisk A/S | GLP-1 prodrugs |
JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
EP2895506A1 (en) * | 2012-09-17 | 2015-07-22 | Imperial Innovations Limited | Peptide analogues of glucagon and glp1 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
RU2016134425A (ru) | 2014-02-18 | 2018-03-20 | Ново Нордиск А/С | Стабильные аналоги глюкагона и их применение для лечения гипогликемии |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
CR20170164A (es) | 2014-10-24 | 2017-08-29 | Merck Sharp & Dohme | Coagonistas de los receptores de glucagón y de glp-1 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
MA51017A (fr) * | 2017-12-07 | 2021-03-17 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
ES2075196T3 (es) | 1989-02-17 | 1995-10-01 | Chiron Mimotopes Pty Ltd | Metodo para el uso y la sintesis de peptidos. |
CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Gip様活性を有するポリペプチド誘導体及びその用途 |
US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
AU2263197A (en) | 1996-02-06 | 1997-08-28 | Eli Lilly And Company | Diabetes therapy |
NZ334595A (en) | 1996-09-09 | 2000-08-25 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
AU6294899A (en) | 1998-10-07 | 2000-04-26 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
WO2000058360A2 (en) | 1999-03-29 | 2000-10-05 | Uutech Limited | Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
US6458493B2 (en) * | 1999-06-04 | 2002-10-01 | International Business Machines Corporation | Method to control nested to isolated line printing |
EP1356295A2 (en) | 2000-04-27 | 2003-10-29 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucos |
US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
JP2004503565A (ja) | 2000-06-14 | 2004-02-05 | サイトヴァックス・バイオテクノロジーズ・インコーポレーテッド | 構造特異的ペプチドを生産するためのコイルドコイル構造的骨格の使用 |
BR0111562A (pt) | 2000-06-16 | 2003-04-15 | Lilly Co Eli | Análogos de peptìdeo 1 semelhantes ao glucagon |
AU2001279526A1 (en) | 2000-08-02 | 2002-02-13 | Theratechnologies Inc. | Modified peptides with increased potency |
US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
EP1351984A2 (en) | 2000-12-13 | 2003-10-15 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
JP2005509409A (ja) | 2001-08-08 | 2005-04-14 | ジェンザイム・コーポレーション | 糖尿病および他の血糖疾患の治療方法 |
JP2005508895A (ja) | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Glp−1および基礎インスリンの予備混合物 |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
CA2463908A1 (en) | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7179788B2 (en) | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
AU2002351752A1 (en) | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
US20060252916A1 (en) | 2002-06-04 | 2006-11-09 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
EP1515746A2 (en) | 2002-06-11 | 2005-03-23 | Eisai Co. Ltd | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
WO2003105760A2 (en) | 2002-06-15 | 2003-12-24 | Enteromed, Inc. | Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip) |
WO2004022004A2 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
WO2004093823A2 (en) | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
US7259234B2 (en) | 2003-05-15 | 2007-08-21 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
EP1633391B1 (en) | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
PL1633390T3 (pl) | 2003-06-03 | 2012-06-29 | Novo Nordisk As | Stabilizowane kompozycje farmaceutyczne peptydu glp-1 |
MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
US20050124550A1 (en) | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
WO2005027978A2 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
DE602004026113D1 (de) * | 2003-12-18 | 2010-04-29 | Novo Nordisk As | Glp-1-verbindungen |
US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
AU2006213607A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
JP2008533104A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | Glp−1受容体の二量体ペプチドアゴニスト |
WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
ES2350852T3 (es) | 2005-05-13 | 2011-01-27 | Eli Lilly And Company | Compuestos glp-1 pegilados. |
KR101349808B1 (ko) | 2005-06-13 | 2014-02-13 | 임페리얼 이노베이션스 리미티드 | 섭취행동에 관한 신규 화합물들 및 이들의 효능 |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
AU2006289259A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
EP1943274A2 (en) | 2005-09-08 | 2008-07-16 | Uutech Limited | Treatment of diabetes related obesity |
WO2007056362A2 (en) * | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
JP5312054B2 (ja) | 2006-03-15 | 2013-10-09 | ノボ・ノルデイスク・エー/エス | アミリンとインスリンの混合物 |
CN101432025B (zh) | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
EP2057188B1 (en) | 2006-08-17 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
EP2057189B1 (en) | 2006-08-25 | 2013-03-06 | Novo Nordisk A/S | Acylated exendin-4 compounds |
EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
EP2111414B1 (en) * | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
CN101842386A (zh) | 2007-09-05 | 2010-09-22 | 诺沃-诺迪斯克有限公司 | 截短的glp-1衍生物和它们的治疗用途 |
WO2009035540A2 (en) | 2007-09-07 | 2009-03-19 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
US20100222251A1 (en) | 2007-09-11 | 2010-09-02 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
US8261025B2 (en) | 2007-11-12 | 2012-09-04 | International Business Machines Corporation | Software pipelining on a network on chip |
WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
BRPI0906643A2 (pt) | 2008-02-01 | 2019-09-10 | Ascendis Pharma As | profármaco compreendendo um conjugado fármaco-ligante |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
EA019203B9 (ru) | 2008-06-17 | 2014-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты глюкагонового рецептора/glp-1-рецептора |
KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
TWI489992B (zh) | 2008-12-19 | 2015-07-01 | 印地安那大學研究及技術公司 | 醯胺系胰高血糖素超級家族之胜肽前驅藥物 |
CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY |
ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2008
- 2008-10-23 ES ES08845852.6T patent/ES2509883T3/es active Active
- 2008-10-23 EP EP08845852.6A patent/EP2217701B9/en active Active
- 2008-10-23 MX MX2010004297A patent/MX2010004297A/es active IP Right Grant
- 2008-10-23 CA CA2707861A patent/CA2707861A1/en not_active Abandoned
- 2008-10-23 JP JP2010532154A patent/JP5669582B2/ja not_active Expired - Fee Related
- 2008-10-23 US US12/739,342 patent/US8981047B2/en not_active Expired - Fee Related
- 2008-10-23 WO PCT/US2008/080973 patent/WO2009058662A2/en active Application Filing
- 2008-10-23 AU AU2008318986A patent/AU2008318986B2/en not_active Ceased
- 2008-10-29 CL CL2008003222A patent/CL2008003222A1/es unknown
- 2008-10-29 AR ARP080104739A patent/AR069110A1/es unknown
- 2008-10-30 PE PE2008001856A patent/PE20091393A1/es not_active Application Discontinuation
- 2008-10-30 TW TW097141806A patent/TW200920404A/zh unknown
-
2010
- 2010-11-12 HK HK10110565.2A patent/HK1143994A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2217701B9 (en) | 2015-02-18 |
EP2217701B1 (en) | 2014-07-02 |
EP2217701A4 (en) | 2011-06-15 |
MX2010004297A (es) | 2010-05-03 |
AU2008318986A1 (en) | 2009-05-07 |
CL2008003222A1 (es) | 2009-02-27 |
WO2009058662A3 (en) | 2010-01-07 |
AU2008318986B2 (en) | 2014-12-04 |
JP5669582B2 (ja) | 2015-02-12 |
US8981047B2 (en) | 2015-03-17 |
HK1143994A1 (en) | 2011-01-21 |
TW200920404A (en) | 2009-05-16 |
WO2009058662A2 (en) | 2009-05-07 |
JP2011502155A (ja) | 2011-01-20 |
CA2707861A1 (en) | 2009-05-07 |
EP2217701A2 (en) | 2010-08-18 |
US20120122783A1 (en) | 2012-05-17 |
PE20091393A1 (es) | 2009-09-11 |
AR069110A1 (es) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2509883T3 (es) | Antagonistas de glucagón | |
JP2013518115A5 (es) | ||
AR065349A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
ES2558330T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
ES2351661T3 (es) | Péptido-2 análogo al glucagón. | |
ES2277676T3 (es) | Antagonistas de los peptidos glp-2 intestinotroficos. | |
NO20092774L (no) | HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette | |
MXPA06010347A (es) | Agonistas de receptor selectivo de y2 para intervenciones terapeuticas. | |
ES2651946T3 (es) | Utilización de péptidos CD31 en el tratamiento de trastornos trombóticos y autoinmunes | |
PE20120021A1 (es) | Mutantes fgf21 | |
RU2011129784A (ru) | Основанные на амидах пролекарства пептидов глюкагонового надсемейства | |
EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
PE20091405A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
PE20091067A1 (es) | Variantes de peptidos natriureticos de tipo c | |
RU2015101697A (ru) | Аналоги глюкагона, обладающие активностью рецептора gip | |
AR071874A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
WO2001058493A8 (en) | Conjugates of follicle stimulating hormones | |
ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
WO2005089790A3 (en) | Y2/y4 selective receptor agonists for therapeutic interventions | |
WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy |